Pricing Transparency Policies Not Suited To Generics, GPhA Argues
Executive Summary
Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.
You may also be interested in...
The US Drug Pricing Hearing Pharma Wants
Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.
The US Drug Pricing Hearing Pharma Wants
Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.
GPhRMA? Generic Trade Group Picks Up Another Exec From Brand Association
PhRMA Senior Counsel Jeffrey Francer will become GPhA's General Counsel in mid-November.